regulatory
confidence high
sentiment negative
materiality 0.70
Xilio Therapeutics receives Nasdaq deficiency notice for bid price below $1.00 per share
Xilio Therapeutics, Inc.
- Received Nasdaq notice on Sept 10, 2024; common stock bid price below $1.00 for 30 consecutive business days.
- Has 180 calendar days until March 10, 2025 to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not compliant, may transfer to Nasdaq Capital Market for additional 180-day period, subject to other listing standards.
- Company monitoring bid price and evaluating options; no assurance regaining compliance will be achieved.